Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance

Vanguard Real Estate Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Vanguard Real Estate Index Fund ETF — how do they compare? Sanofi SA trades at $44.08 (market cap $104.30B), while Vanguard Real Estate Index Fund ETF trades at $97.36. The key difference: Sanofi SA pays a 5.55% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.

SNYVNQ
Market Cap
$104.30B
Sector
Health
52-Week High
$52.34$100.95
52-Week Low
$41.33$87.00
Enterprise Value
$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.

The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.

Vanguard Real Estate Index Fund ETF

VNQ, the Vanguard Real Estate ETF, trades at $97.31, up 0.21% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF's financial ratios are not disclosed in the provided data, limiting fundamental assessment. Recent news highlights institutional selling, with firms like City Holding Co. and Bank of America reducing positions, while media comparisons focus on VNQ's U.S. REIT exposure and low fees versus global alternatives.

Outlook remains cautious due to bearish technicals and institutional outflows, though the neutral oscillator reading and upcoming dividend in June 2026 offer some balance. Risks include interest rate sensitivity and real estate market volatility, but the ETF's low expense ratio and diversification provide a defensive income option for long-term investors amid economic uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY

About Vanguard Real Estate Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.

Read more on VNQ